

Stephanie Lheureux

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9290858/stephanie-lheureux-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

2,400
citations

24
h-index

47
g-index

106
ext. papers

3,630
ext. citations

8.4
avg, IF

5.81
L-index

#	Paper	IF	Citations
85	Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria.. <i>European Heart Journal - Case Reports</i> , 2022 , 6, ytab478	0.9	1
84	Survival with Cemiplimab in Recurrent Cervical Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 544-555	59	11
83	MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	0
82	Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. <i>Cancer Research Communications</i> , 2022 , 2, 293-306		0
81	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa115	4.6	3
80	New approaches for targeting platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021 , 77, 167-181	12.7	13
79	The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2021 , 161, 601-612	4.9	3
78	Can variant negative be high-grade serous ovarian carcinoma? A case series. <i>Gynecologic Oncology Reports</i> , 2021 , 36, 100729	1.3	
77	Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 225, 658.e1-658.e9	6.4	0
76	Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. <i>Future Oncology</i> , 2021 , 17, 877-892	3.6	5
75	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021 , 4, 274-281	6.7	5
74	Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature. <i>Current Oncology</i> , 2021 , 28, 661-670	2.8	1
73	Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2021 , 397, 281-292	40	32
72	ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1471-1475	3.5	4
71	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102294	14.4	2
70	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. <i>Modern Pathology</i> , 2020 , 33, 2361-2377	9.8	3
69	Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer. <i>Cancer</i> , 2020 , 126, 2139-2145	6.4	

68	Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma. <i>Clinical Chemistry</i> , 2020 , 66, 352-362	5.5	11
67	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). <i>Clinical Cancer Research</i> , 2020 , 26, 2477-2488	12.9	4
66	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 903-915	3.5	15
65	Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study. <i>Gynecologic Oncology</i> , 2020 , 157, 745-753	4.9	6
64	EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. <i>Clinical Cancer Research</i> , 2020 , 26, 4206-4215	12.9	30
63	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020 , 9, 337	3.6	2
62	Adjuvant treatment in early stage cervical cancer-does more equal better?. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1467-1468	3.5	
61	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.. <i>Nature Cancer</i> , 2020 , 1, 873-881	15.4	89
60	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors 2020 , 8,		12
59	Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1256-1257	3.5	1
58	PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3468-3493	2.2	60
57	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 539-545	4.9	3
56	Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer. <i>Journal of Oncology Practice</i> , 2019 , 15, e1066-e1075	3.1	10
55	Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , 2019 , 19, 339-348	31.3	17
54	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2019 , 69, 280-304	220.7	292
53	mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 346-352	3.5	21
52	Epithelial ovarian cancer. <i>Lancet, The</i> , 2019 , 393, 1240-1253	40	463
51	Tailoring Ovarian Cancer Treatment: Implications of Mutations. <i>Cancers</i> , 2019 , 11,	6.6	34

50	The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2449-2459	2.2	11
49	DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 5729-5731	12.9	5
48	Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer. A Princess Margaret Consortium IG-CIG Phase II Trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5521-5521	2.2	10
47	Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5580-5580	2.2	1
46	Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a -mutated low-grade serous ovarian cancer patient. <i>Journal of Physical Education and Sports Management</i> , 2019 , 5,	2.8	4
45	FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 238-250	8.8	130
44	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report. <i>Gynecologic Oncology</i> , 2018 ,	4.9	11
43	Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?. <i>Clinical Cancer Research</i> , 2018 , 24, 3233-3235	12.9	2
42	Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective. <i>Obstetrics and Gynecology International</i> , 2018 , 2018, 1867238	2	14
41	Rucaparib: a novel PARP inhibitor for advanced ovarian cancer. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 605-617	4.4	16
40	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. <i>Clinical Cancer Research</i> , 2018 , 24, 6168-6174	12.9	30
39	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , 2018 , 4, e173776	13.4	72
38	Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. <i>Genome Medicine</i> , 2018 , 10, 81	14.4	46
37	The role of niraparib for the treatment of ovarian cancer. <i>Future Oncology</i> , 2018 , 14, 2565-2577	3.6	6
36	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , 2017 , 23, 4086-4094	12.9	83
35	Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1240-1249	2.2	59
34	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017 , 145, 584-594	4.9	58
33	Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 927-943	5.4	15

32	Niraparib for the treatment of ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 631-640	4	20
31	Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology. <i>Methods</i> , 2017 , 130, 23-35	4.6	24
30	Treatment strategies for endometrial cancer: current practice and perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017 , 29, 47-58	2.4	96
29	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 71-83	1.1	6
28	Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. <i>European Journal of Cancer</i> , 2016 , 59, 99-108	7.5	28
27	Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5586-5586 ²	2.2	586 ²
26	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 36, e247-e257	7.1	6
25	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e247-57	7.1	9
24	Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. <i>Frontiers in Oncology</i> , 2016 , 6, 119	5.3	12
23	The role of cediranib in ovarian cancer: current status and further investigation. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 855-865	1.1	
22	Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy. <i>Molecular Oncology</i> , 2016 , 10, 981-929	7.9	48
21	Safety evaluation of olaparib for treating ovarian cancer. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1305-161	1.1	12
20	Targeting the microenvironment in ovarian cancer. <i>Lancet Oncology, The</i> , 2015 , 16, 485-6	21.7	1
19	Ovarian cancer treatment: The end of empiricism?. <i>Cancer</i> , 2015 , 121, 3203-11	6.4	27
18	Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma. <i>International Journal of Cancer</i> , 2015 , 136, E340-50	7.5	17
17	Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention. <i>Gynecologic Oncology</i> , 2015 , 138, 235-7	4.9	4
16	Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. <i>BJU International</i> , 2015 , 115, 65-73	5.6	4
15	Genomic characterization of long-term responders to olaparib.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5566-5566	2.2	2

14	An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16586-e16586	2.2	1
13	Non-target progression--the fine line between objectivity and subjectivity. <i>European Journal of Cancer</i> , 2014 , 50, 3271-2	7.5	
12	PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. <i>Cancer Letters</i> , 2014 , 348, 38-49	9.9	36
11	Recent and current Phase II clinical trials in endometrial cancer: review of the state of art. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 773-92	5.9	13
10	A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. <i>Gynecologic Oncology</i> , 2014 , 134, 274-80	4.9	45
9	Olaparib for the treatment of ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 497-508	1.1	8
8	(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer. <i>Translational Oncology</i> , 2013 , 6, 586-95	4.9	17
7	Nanocarriers for the targeted treatment of ovarian cancers. <i>Biomaterials</i> , 2013 , 34, 1073-101	15.6	56
6	Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013 , 18, 492-508	5.4	36
5	F18-choline, a novel PET tracer for parathyroid adenoma?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 3111-2	5.6	50
4	Evaluation of current practice: management of chemotherapy-related toxicities. <i>Anti-Cancer Drugs</i> , 2011 , 22, 919-25	2.4	12
3	Two novel variants in the 3'UTR of the BRCA1 gene in familial breast and/or ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 885-91	4.4	15
2	Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 615-30	5.4	7
1	Ivory vertebra appearing photopenic on Tc-99m MDP bone scan: demonstration by SPECT/CT. <i>Clinical Nuclear Medicine</i> , 2008 , 33, 479-81	1.7	5